necrotizing encephalomyelopathy, subacute, of Leigh, adult

Summary

necrotizing encephalomyelopathy, subacute, of Leigh, adult (MONDO:0008069) is a disease. A subtype of Leigh syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	necrotizing encephalomyelopathy, subacute, of Leigh, adult
Mondo ID	MONDO:0008069
MeSH	C563530
OMIM	161700
UMLS	C1834340
MedGen	331718
GARD	0024598
Is cancer (heuristic)	no

Also known as: necrotizing encephalomyelopathy, subacute, of Leigh, adult

Disease family

This is a subtype of Leigh syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › developmental anomaly of metabolic origin › inborn mitochondrial metabolism disorder › mitochondrial oxidative phosphorylation disorder › Leigh syndrome › necrotizing encephalomyelopathy, subacute, of Leigh, adult

Related subtypes (3): congenital lactic acidosis, Saguenay-Lac-Saint-Jean type, maternally-inherited Leigh syndrome, Leigh syndrome with cardiomyopathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.